The goal of this clinical trial is to study and describe the effects of bilateral tDCS
applied to dorso-lateral-prefrontal cortex (DLPC) in patients with drug-resistant migraine in
terms of reduction in frequency of pain, impact of pain in daily life, quality of sleep and
psychological measures. We finally planned to include high frequency and chronic migraine
patients.
The main questions it aims to answer are:
- Will bilateral DLPC tDCS be feasible, well tolerated and safe in drug resistant migraine
patients?
- Will bilateral DLPC tDCS be effective in reducing pain frequency, intensity and its
impact in daily life activities?
- Will bilateral DLPC tDCS be effective in ameliorating sleep and psychological associated
symptoms?
- Will bilateral DLPC tDCS be such effective in reducing pain frequency, intensity and its
impact in daily life activities as anti-CGRP treatments?
Participants will undergo 2 tDCS sessions daily for 2 consecutive weeks. Patients will be
blinded to treatment and will be divided in two groups (real vs placebo). A third group of
patients, age-matched to the other two, will undergo anti-CGRP treatment. Patients will be
asked to complete Patient-Reported Outcomes (PROMs) scales at baseline, one week after the
end of the treatment and at 6 months after the end of the treatment.
Researchers (blinded to the treatment) will compare the group that underwent real tDCS
treatment vs the one that underwent placebo tDCS vs the one that underwent anti-CGRP drugs to
see if bilateral DLPC tDCS is effective in reducing migraine frequency, intensity and impact
and if bilateral DLPC tDCS is such effective as anti-CGRP treatment.